Clinical trials: Controlled Hypertension
Chronic Kidney Disease
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor [ASI]) in…
- Trial name
- NCT06150924
- Where
- 44 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mineralys Therapeutics Inc.
Hypertension
Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension
The study is being conducted to evaluate the safety and efficacy and Pharmacokinetics/Pharmacodynamics of SHR0532 in subjects with mild hypertension for 4 weeks.
- Trial name
- NCT03971929
- Testing
- SHR0532, Hydrochlorothiazide 25 mg
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chronic Thromboembolic Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
The purpose of the study is to evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary hypertension (CTEPH).
- Trial name
- MACiTEPH (NCT04271475)
- Testing
- Macitentan
- Where
- 168 sites in United States, Argentina and 31 more
- Volunteers
- 127 people
- Sponsor
- Actelion
Glaucoma
MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)
The clinical study compares safety and efficacy of MK0507A (dorzolamide 1.0% / timolol 0.5%) with 1) timolol 0.5% and with 2) concomitant therapy with dorzolamide 1.0% / timolol 0.5% in patients with glaucoma and ocular…
- Trial name
- NCT00449956
- Testing
- dorzolamide hydrochloride (+) timolol maleate, Comparator: timolol maleate, Comparator: dorzolamide hydrochloride
- Volunteers
- 474 people
- Sponsor
- Merck Sharp & Dohme LLC
Refractory Hypertension
TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension
A pilot study of subjects with refractory hypertension (on 3 concomitant agents with SBP > 140 mmHg and a DBP > 90 mmHg) randomized in a double-blind fashion to receive 4 single escalating doses of study medication in clinic.
- Trial name
- NCT00899977
- Testing
- TC-5214
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Targacept Inc.
Hypertension
Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension
This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult Chinese patients with mild to moderate essential hypertension.
- Trial name
- NCT00367094
- Testing
- Benazepril plus hydrochlorothiazide
- Where
- China
- Volunteers
- 296 people
- Sponsor
- Novartis
Hypertension
Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide
Study to compare the level of blood pressure control in hypertensive, hypertensive diabetics and hypertensive with renal insufficiency (observed data) in the study population, with the objectives of the High Authority for Health…
- Trial name
- NCT02248129
- Testing
- Telmisartan and hydrochlorothiazide
- Volunteers
- 4,255 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Hypertension
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.
- Trial name
- NCT00091715
- Testing
- bosentan
- Where
- 34 sites in United States, Australia and 12 more
- Volunteers
- 185 people
- Sponsor
- Actelion
Primary Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
To evaluate the safety and efficacy of PF-04217329.
- Trial name
- NCT00572455
- Testing
- PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose
- Where
- 23 sites in United States
- Volunteers
- 318 people
- Sponsor
- Pfizer
Glaucoma, Open-Angle, Ocular Hypertension
Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma
The purpose of this study is to evaluate the safety and potential efficacy of a new drug, OT-730 ophthalmic solution (eye drops), in reducing intraocular pressure in the eyes of patients with open angle glaucoma or ocular…
- Trial name
- NCT00753168
- Testing
- OT-730 ophthalmic solution, timolol maleate ophthalmic solution
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Othera Pharmaceuticals
Hypertension
Tadalafil in Subjects With Mild to Moderate Hypertension
Purpose: The primary objective of this study is to evaluate the efficacy and safety of tadalafil when administered once daily at doses of 5 and 20 mg to adult subjects for 8 weeks with mild to moderate hypertension.
- Trial name
- NCT00157326
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Eli Lilly and Company
Heart Failure
"ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure
This study was designed to determine if patients, who have both high blood pressure and heart failure and are currently receiving drug treatment for heart failure, have an improvement in their heart failure signs and symptoms and…
- Trial name
- NCT00219011
- Testing
- aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 280 people
- Sponsor
- Novartis
High Cardiovascular Risk, Hypertension
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
- Trial name
- KARDIA-3 (NCT06272487)
- Testing
- Zilebesiran
- Where
- 195 sites in United States, Australia and 4 more
- Volunteers
- 375 people
- Sponsor
- Alnylam Pharmaceuticals
Glaucoma
A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650)
The purpose of this study is to evaluate the safety and tolerability of INS117548 ophthalmic solution.
- Trial name
- NCT00767793
- Testing
- INS117548
- Volunteers
- 84 people
- Sponsor
- Merck Sharp & Dohme LLC
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension
This study assessed the efficacy of LCZ696 in Japanese patients with essential hypertension
- Trial name
- NCT01599104
- Testing
- LCZ696, Olmesartan
- Where
- 61 sites in Japan
- Volunteers
- 1,161 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)
The purpose of this study is to evaluate the blood pressure (BP)-lowering efficacy of tonlamarsen in adult participants who, despite taking 2 or more antihypertensive medications, have not achieved their target blood pressure…
- Trial name
- NCT06864104
- Testing
- Tonlamarsen
- Where
- 39 sites in United States
- Volunteers
- 206 people
- Sponsor
- Kardigan, Inc.
Glaucoma, Ocular Hypertension
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
The purpose of this study is to evaluate how tolerable, safe, and effective it is to give INO-8875 eye drops to adults with glaucoma or ocular hypertension.
- Trial name
- NCT01123785
- Testing
- INO-8875
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Glaucoma
PRM-151 in the Prevention of Scarring Following Trabeculectomy
This study will assess the safety and tolerability of PRM-151 administered as a subconjunctival injection and explore the effect of PRM-151 on various correlates of the wound healing process that occurs in the eye after glaucoma…
- Trial name
- NCT01064817
- Testing
- PRM-151
- Where
- 14 sites in Belgium, Czechia and 2 more
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
Uncontrolled Hypertension, Resistant Hypertension
A Study Evaluating the Efficacy and Safety of SYH2072 Tablets In Hypertensive Patients
SYH2072 is a highly selective aldosterone synthase inhibitor. This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of SYH2072 tablets in patients with…
- Trial name
- NCT07911735
- Testing
- SYH2072 Tablets
- Volunteers
- 264 people
- Sponsor
- InnovStone Therapeutics Limited
Type 2 Diabetes
Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of pioglitazone-azilsartan, once daily (QD), in subjects with type 2 diabetes mellitus with poor glycemic control.
- Trial name
- NCT00376181
- Testing
- Pioglitazone and Azilsartan, Pioglitazone
- Where
- 73 sites in United States, Argentina and 3 more
- Volunteers
- 96 people
- Sponsor
- Takeda